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450. Electron microscopy revealed a coronary EG of 300 nm, 
reduced to 20 nm after heparinase. Cultured endothelial 
cells possessed an EG of 20 nm to begin with.  Conclusions: 
Albumin induces greater endothelial shear stress than HES, 
despite lower viscosity, provided the EG contains negative 
groups. HES 450 causes some NO-mediated dilatation via 
even a rudimentary EG. Cultured endothelial cells express 
only a rudimentary glycocalyx, limiting their usefulness as a 
model system.  Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 The physiological importance of the endothelial gly-
cocalyx (EG) had been ignored for many years. Modern 
preparation and staining techniques, however, have re-
vealed a glycocalyx with a relevant thickness ranging 
from 0.3 to more than 1.0   m  [1–5] throughout the vas-
cular bed. This EG consists of extracellular domains of 
molecules like transmembrane syndecans and mem-
brane-bound glypicans that both contain many covalent-
ly bound, negatively charged heparan sulfate and chon-
droitin sulfate groups  [6] . The observation of intercalated 
plasma components, mainly albumin, led to the modern 
concept of the endothelial surface layer (ESL) which de-
nies access of blood cells and large molecules to the en-
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 Abstract 
 Background: Shear stress induces coronary dilatation via 
production of nitric oxide (NO). This should involve the en-
dothelial glycocalyx (EG). A greater effect was expected of 
albumin versus hydroxyethyl starch (HES) perfusion, be-
cause albumin seals coronary leaks more effectively than 
HES in an EG-dependent way.  Methods: Isolated hearts 
(guinea pigs) were perfused at constant pressure with Krebs-
Henseleit buffer augmented with 1/3 volume 5% human al-
bumin or 6% HES (200/0.5 or 450/0.7). Coronary flow was 
also determined after EG digestion (heparinase) and with ni-
tro- L -arginine (NO- L -Ag).  Results: Coronary flow (9.50  8 
1.09, 5.10  8 0.49, 4.87  8 1.19 and 4.15  8 0.09 ml/min/g for 
‘albumin’, ‘HES 200’, ‘HES 450’ and ‘control’, respectively, n = 
5–6) did not correlate with perfusate viscosity (0.83, 1.02, 
1.24 and 0.77 cP, respectively). NO- L -Ag and heparinase di-
minished dilatation by albumin, but not additively. Alone 
NO- L -Ag suppressed coronary flow during infusion of HES 
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dothelial surface  [6–9] and, under physiological circum-
stances, likely covers adhesion molecules like selectins 
and integrins  [10, 11] , preventing pathological adhesive-
ness of the vascular wall  [12] . Consequently, several im-
portant properties are to be attributed to the EG: it is in-
volved in inflammatory processes and immune reactions 
 [13, 14] and has been identified as a competent barrier 
against extravasation of fluids and colloids  [4, 8, 15–17] . 
Other work suggested that the EG should play a key role 
in mediating shear stress to the endothelial surface and 
in triggering the production of vasoregulatory agents, 
mainly nitric oxide (NO)  [18–23] .
 While the intracellular signaling pathway of shear 
stress-induced vasodilatation is well explored  [24] , the 
transduction of this stress to the endothelial surface re-
mains rather unclear. The production of NO, catalyzed 
by endothelial NO synthase, responds, according to ex-
periments with monolayers of endothelial cells from hu-
man umbilical vein (HUVEC) and bovine aorta, in a bi-
phasic manner to shear stress  [18, 19, 21] . An initial rapid 
production phase (G protein and Ca 2+ -dependent, influ-
enced by rate of change of shear more than by the absolute 
shear level) is followed by a phase of lower production of 
NO (G protein and Ca 2+ -independent, influenced by the 
absolute shear level  [21] ).
 Most of the studies dealing with NO release induced 
by shear stress, however, are limited by the employed ex-
perimental model, i.e., cultured endothelial cells, pre-
sumably possessing only a rudimentary EG not compa-
rable to the endothelial cell surface in vivo  [18, 19] . Ad-
ditionally, this model does not deliver any functional data 
to quantify the effect of an applied shear stress on vascu-
lar flow, the main objective of releasing NO. Also, the 
ability of specified colloids to transmit shear stress to the 
endothelial cells via the individually generated ESL has 
not been compared quantitatively in situ.
 In recent work on the isolated guinea pig heart, we sub-
stantiated that the role of colloids concerning vascular 
permeability depends predominantly on their ability to 
interact with the EG to form an ESL  [8, 17] . We observed 
an impressive sealing effect of human albumin during 
perfusion under constant flow, a mode in which the coro-
nary system was able to alleviate shear stress by dilating.
 The aim of the current study was to compare the func-
tional impact of albumin and artificial colloids on vaso-
dilatation induced by shear stress in the whole organ 
model. Due to its interaction with the EG we expected 
albumin to be more effective than artificial alternatives. 
In order to augment shear stress-induced vasodilatation, 
constant pressure perfusion of the coronary system was 
implemented. Because coronary endothelial cells in situ 
possess a glycocalyx of some 200–300 nm thickness  [4, 8, 
16] , we additionally checked for the presence of an EG in 
confluent, cultured HUVECs, one of the most common 
‘artificial’ models of the intravascular surface.
 Methods 
 Heart Preparation 
 Guinea pig hearts were isolated and perfused in a modified 
Langendorff mode at constant perfusion pressure of 80 cm H 2 O 
and at 37  °  C with modified Krebs-Henseleit buffer (KHB) as de-
scribed elsewhere  [4, 8, 25] .
 Experimental Protocols 
 Experimental protocols are outlined in  figure 1 .
 Control Groups 
 Time-matched vehicle control values were measured during 
infusion of 1/3 volume of 0.9% saline (‘control’ group), after ad-
ditional pretreatment with heparinase (‘control heparinase’ 
group), or during additional application of nitro- L -arginine (NO-
 L -Ag), a substance known to block the endothelial NO synthase 
(‘control NO- L -Ag’ group; n = 5 each).
 Colloid Groups with Intact Glycocalyx 
 Three different, clinically relevant colloids were added to KHB 
(1/3 volume via the aortic feed line): 5% human albumin, 6% hy-
droxyethyl starch (HES) 200, and 6% HES 450. The resulting 
groups were termed ‘albumin’, ‘HES 200’ and ‘HES 450’ (n = 5, 6 
and 5, respectively).
 Colloid Groups after Heparinase Pretreatment, NO- L -Ag 
Application, or Combined Intervention 
 We performed the same experiments as before, but after pre-
treatment of hearts with heparinase (‘albumin + H’, ‘HES 200 + 
H’ and ‘HES 450 + H’ groups; n = 5, 6 and 5, respectively). In ‘al-
bumin + NO- L -Ag’ and ‘HES 450 + NO- L -Ag’ groups (n = 8 and 
5, respectively), we infused NO- L -Ag during replacement of 1/3 
volume of KHB with 5% human albumin or 6% HES 450 (phase 
III). In two further groups, hearts pretreated with heparinase 
(phase IIA) received NO- L -Ag in addition to 1/3 volume 5% hu-
man albumin or HES 450 (‘albumin + NO- L -Ag + H’ and ‘HES 
450 + NO- L -Ag + H’; n = 5 each).
 Electron Microscopy of Hearts 
 Two additional hearts in each group, treated in the same way 
as described in the respective protocols, were prepared for elec-
tron microscopy. This was performed in modification of the 
method of Vogel et al.  [26] , as described elsewhere  [8, 16] and re-
lied primarily on stabilization of the glycocalyx with the polyva-
lent cation lanthanum (La 3+ ), which binds to the negative charges 
(heparan and chondroitin sulfates). Accordingly, the glyceal 
structure visualized in this manner does not entirely reflect the 
natural state, presumably appearing more orderly and more rigid 
that in vivo. However, it allows a quantitative estimation of the 
thickness of the layer.
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 During electron-microscopic examination (Philips CM 10), 
whole capillary profiles were photographed systematically so that 
all capillaries in a section were photographed with the exception 
of those which were collapsed. This is justified because only cap-
illaries with an open lumen provide a guarantee of having been 
perfused and uniformly stained with the glycocalyx tracer. Only 
in these is it possible to assess the thickness of the layer. The pho-
tographed capillaries presented here reflect the general and fairly 
uniform changes seen in the respective perfusion groups. Black 
and white images of approximately 50 capillaries of at least two 
hearts of each group were compiled. Electron-microscopic views 
were assessed qualitatively only.
 Cultivation and Electron Microscopy of HUVEC 
 Endothelial cells freshly isolated from human umbilical veins 
(2nd passage) were seeded onto   -slides (IBIDI, Munich, Ger-
many) and grown to three stages of maturity: nonconfluent, con-
fluent and onset of capillarization. HUVEC monolayers (n = 5) 
were prepared for electron microscopy in a manner comparable 
to that described above for the hearts at the end of the experimen-
tal protocols.
 Statistical Analysis 
 All data are presented as mean  8 SD, with n indicating the 
number of experiments. Comparisons were made using analysis 
of variance. Post hoc testing was performed using the Student-
Newman-Keuls method for multiple comparisons. A p value less 
than 0.05 was considered to be significant.
 Results 
 Table 1 provides an overall listing of coronary flow 
during control conditions (1/3 volume of 0.9% saline add-
ed to the Krebs-Henseleit perfusate). In the absence of any 
further intervention, there was no time-dependent altera-
tion in coronary vascular tone over the 20-min period of 
observation. While heparinase pretreatment did not cause 
any measurable change in coronary flow, a slight decrease 
developed with time during NO- L -Ag infusion, indicating 
that this intervention is able to increase basal vascular 
tone even in a colloid-free perfusion mode. The effect was 
significant from the 6th minute of application onward.
 Coronary flow did not change in the saline group, 
which serves as the vehicle control to disclose any effects 
arising from a dilution of the KHB by 1/3 volume ( fig. 2 ). 
Coronary effluent flow values during infusion of the 
three different colloid preparations are compared in  fig-
ure 2 . While infusion of the artificial colloid HES did not 
lead to any significant change versus basal or versus con-
trol, irrespective of the molecular weight, albumin caused 
a dramatic increase in coronary flow. This effect devel-
oped over time and apparently had not quite come to an 
end by 20 min of application. The exact coronary flow 
Phase I:
Heart
preparation
Phase II:
Equilibration
Phase III:
Colloid/saline infusion
± NO-L-Ag
Experimental protocol for hearts with intact glycocalyx
Experimental protocol with heparinase pretreatment
Heparinase
pretreatment
–15 0 20
–30 –15 0 20
Phase I:
Heart
preparation
Phase II:
Equilibration
Phase IIA: Phase III:
Colloid/saline infusion
± NO-L-Ag
min
min
 Fig. 1. Experimental protocols. Hearts were perfused with KHB 
from the onset of preparation during phases I (preparation, 15 
min), II (equilibration, 15 min), and IIA (optional heparinase pre-
treatment). During phase III, 1/3 volume KHB was replaced by 
isotonic saline (vehicle control), or by a solution of one of three 
different types of colloids.  Constant application was achieved by 
repeatedly measuring the total coronary inflow and manually ad-
justing the rate of infusion. Optional application of NO- L -Ag
(10 –5   M ) was performed throughout phase III in the respective 
groups. Despite additional infusion of 1/3 volume of ungassed so-
lutions to the KHB, the resulting perfusate reached an oxygen 
tension between 390 and 420 mm Hg in all hearts. According to 
previous experiments, this represented a ‘luxury oxygenation’, 
never limiting oxygen consumption. Coronary flow was mea-
sured after equilibration (basal value) and at 1, 2, 3, 4, 6, 8, 10, 15 
and 20 min of phase III in each protocol. Heparinase pretreat-
ment: application of a total of 10 IU of heparinase/15 min during 
optional phase IIA. 
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values at this time were 9.50  8 1.09, 5.10  8 0.49 and 4.87 
 8 1.19 ml/min/g for the albumin, HES 200 and HES 450 
groups, respectively.
 As can be seen in  figure 3 a, the increase in flow caused 
by albumin was diminished by NO- L -Ag infusion or hep-
arinase pretreatment, or by both interventions when per-
formed in one and the same heart. The 20-min values 
were 6.23  8 0.68, 5.38  8 1.31 and 5.11  8 1.03 ml/min/g 
for the albumin + NO- L -Ag, albumin + H, and albumin 
+ NO- L -Ag + H groups, respectively. Thus, while 10   M 
NO- L -Ag by itself did not cause full inhibition of the al-
bumin-induced dilatation, the values after heparinase 
were not significantly higher than in the time-matched 
control heparinase group ( table 1 ). Also, the effect of NO-
 L -Ag was not additive to that of heparinase in the case of 
albumin. In contrast, during infusion of HES 450, block-
ing formation of NO by application of NO- L -Ag, but not 
stripping away the heparan sulfates from the EG signifi-
cantly suppressed the coronary flow rate ( fig. 3 b). The 
20-min values were 4.87  8 1.19, 4.55  8 0.78, 3.41  8 0.42 
and 3.91  8 1.01 ml/min/g for the HES 450, HES 450 + H, 
HES 450 + NO- L -Ag and HES 450 + NO- L -Ag + H groups, 
respectively. This finding suggests that the big HES mol-
ecule may be able to elicit some production of NO via 
shear stress by an interaction even with a rudimentary 
EG. Fittingly, pretreatment with heparinase also had no 
significant effect on coronary flow in hearts perfused 
with HES 200 (20 min value 5.10  8 0.49 ml/min/g with 
and without heparinase, data not shown).
 With application of 10   M NO- L -Ag preventing gen-
eration of NO, the measured coronary flows of the albu-
min + NO- L -Ag and HES 450 + NO- L -Ag groups were 
still significantly different (6.23  8 0.68 and 3.41  8 0.42 
ml/min/g at 20 min, respectively, p  ! 0.05).
 Table 2 provides dynamic viscosities and colloid os-
motic pressures of the respective perfusates. As can be 
seen in  table 2 and  figure 2 , colloid-induced, flow-depen-
dent coronary dilatation does not correlate with dynamic 
viscosity when colloids of a different chemical nature are 
compared. When perfusing with KHB plus albumin the 
dynamic viscosity is comparable to that pertaining to col-
loid-free perfusion, but flow was doubled. In contrast, the 
viscosity after adding 1/3 volume 6% HES 450 is almost 
twice as high as that of KHB, while the flow remained un-
changed. Again, the flow in the HES 450 + NO- L -Ag 
group was identical to that observed after 20 min in the 
control NO- L -Ag group (compare  fig. 3 b and  table 1 ).
Group Time (from start of phase III)
4 min 10 min 15 min 20 min
Control 4.1380.06 4.1880.21 4.1580.09 4.1580.09
Control heparinase 4.1980.13 4.1780.08 4.1680.10 4.1880.07
Control NO-L-Ag 3.9380.23 3.7280.21* 3.5980.22* 3.4980.19*
* p < 0.05 vs. other control groups.
Table 1. Coronary flow during control 
conditions (ml ! min–1 ! g–1, mean 8 
SD, n = 5 each)
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 Fig. 2. Effects of colloids on coronary flow in untreated hearts 
(phase III, albumin, HES 200 and HES 450 groups; n = 5, 6 and 5, 
respectively; mean values  8 SD) in comparison to control condi-
tions (phase III, control group = infusion of saline solution; n = 5; 
dashed line = mean values, SD too small for resolution).  #  p  ! 0.05 
vs. other groups. 
 Glycocalyx-Mediated Coronary 
Dilatation 
J Vasc Res 2007;44:435–443 439
 The colloid osmotic pressure of perfusate containing 
HES 200 is larger than that of the smaller molecular 
weight albumin or the higher molecular weight HES 450 
( table 2 ). However, the latter is still comparable to that of 
albumin, despite the approximately 6- to 7-fold difference 
in average molecular weight (66 vs. 450 kDa). The flow 
effects observed in  figure 2 did not correlate with these 
colloid osmotic pressures.
 Electron microscopy revealed an EG with a thickness 
of approximately 0.2–0.3   m in nonpretreated hearts and 
in hearts treated with NO- L -Ag, both in capillary vessels 
as well as in arteries (see  fig. 4 ). This in situ result stands 
in clear contrast to the situation on a nonpretreated 
monolayer of HUVEC (2nd passage cells), stained by the 
same technique as were the hearts ( fig. 4 b). There is no 
relevant EG on HUVEC, the measured thickness being 
about 20 nm. The same dimension was observed, irre-
spective of the state of confluence of the cultures (results 
not shown).
 Heparinase pretreatment, at first sight, led to a de-
struction of the EG ( fig. 5 ). However, at a higher magni-
fication, a rudimentary glycocalyx could be identified in 
some parts of the vasculature, even after enzymatic di-
gestion ( fig. 5 ). This possibly represents the remaining 
syndecan and glypican scaffold.
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 Fig. 3. Effects of albumin and HES 450 on coronary flow after cardiac pretreatment with heparinase (H) and/or 
in the presence of NO- L -Ag.  a Albumin, albumin + H, albumin + NO- L -Ag and albumin + NO- L -Ag + H groups 
(n = 5, 5, 8 and 5, respectively; mean values  8 SD).  #  p  ! 0.05 vs. other groups.  b HES 450, HES 450 + H, HES 
450 + NO- L -Ag and HES 450 + NO- L -Ag + H groups (n = 5 each; mean values  8 SD).  #  p  ! 0.05 vs. HES 450 
and HES 450 + H groups. 
Table 2. Dynamic viscosities and colloid osmotic pressures of the 
colloid-containing perfusates
Perfusate Dynamic
viscosity, cP
Colloid osmotic 
pressure, mm Hg
KHB 0.77 0.00
KHB with 0.9% salinea 0.77 0.00
KHB with 5% albumina 0.83 5.30
KHB with 6% HES 200a 1.02 5.80
KHB with 6% HES 450a 1.24 4.60
Colloid osmotic pressure determined with Oncometer BMT 
923 (BMT Messtechnik, Berlin, Germany) at 37° C. Kinematic vis-
cosity measured at 37° C with a Viscosimeter Type D60L (Lauda 
Dr. R. Wobser, Lauda-Königshofen, Germany), dynamic (abso-
lute) viscosity calculated as: dynamic viscosity (cP) = kinematic 
viscosity (cSt) ! density (g/ml).
a KHB augmented by 1/3 volume of the respective solution.
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 Discussion 
 The endothelial surface is covered by a glycocalyx con-
sisting of glycoproteins, proteoglycans and associated 
glycosaminoglycan (GAG) side chains  [6, 19] . The main 
type of GAG on the endothelial cell surface are heparan 
sulfates, comprising up to 90% of the GAG pool  [27] . 
Their function as signal transduction molecules has been 
extensively studied  [28] . Heparan sulfate proteoglycans 
can be divided into three different groups on the basis of 
the respective protein backbone: syndecans, glypicans 
and perlecans  [19] . The largest group on the endothelial 
surface, the syndecans, are the only heparan sulfate pro-
teoglycans that penetrate the cytoplasm to interact with 
the cytoskeleton  [29] . They have highly variable extracel-
lular domains and highly conserved intracellular phos-
phorylation sites  [30] . It is assumed that the syndecans 
transduce shear stress into cellular signals  [31, 32] .
 In the isolated perfused organ model, we were able to 
demonstrate that albumin, in contrast to artificial col-
loids, leads to an impressive, significant increase in coro-
nary flow in the constant pressure perfusion mode. This 
phenomenon seems to result largely from shear stress 
transmitted via the glycocalyx on the endothelial surface. 
0.5 µm 0.5 µm
„IVS“IVS
HUVECCEC
„EG“
EG N
10 µm
CEC
M
EG
EG
IVS
10 µm
IVS
EG
CEC
a b
c d
 Fig. 4. Electron-microscopic views of an 
untreated heart (ex vivo preparation): cap-
illary segments ( a ) and small artery ( b ). 
The white patches present in the intravas-
cular zone are artifacts, due to tearing of 
the embedding matrix. Electron-micro-
scopic close up of a coronary endothelial 
cell in situ of an untreated heart ( c ) and of 
a HUVEC in culture ( d ). The EG of the 
heart preparation has a visible thickness
of about 300 nm, in contrast to the un-
physiological conditions of the cultured 
HUVEC, exhibiting a glycocalyx of less 
than 40 nm. CEC = Coronary endothelial 
cell; IVS = intravascular space; M = myo-
cardium; N = cell nucleus. 
100nm10µm
no visible glycocalyx
rudimentary glycocalyx
 Fig. 5. Electron-microscopic view at two 
magnifications of a heart after enzymatic 
digestion of the EG with 10 IU hepari-
nase/15 min. A rudimentary glycocalyx 
remained on some parts of the endothelial 
surface. The edema of hearts with dam-
aged glycocalyx is clearly visible. 
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At least in the guinea pig heart, this leads chiefly to the 
generation of NO, since it was possible to inhibit the flow-
dependent dilatation by blocking the NO synthase al-
most as well as by stripping away the main part of the 
glycocalyx. Interestingly, these two interventions were 
not additive in the case of albumin.
 Maximal coronary flow that can be achieved in these 
heart preparations at 80 cm H 2 O perfusion pressure is 
about 25 ml/min/g  [33, 34] . Thus, the flow increases in-
duced by shear stress seen here were quite moderate. 
Whether the enhancement of basal NO production via 
shear stress alters coronary responses to other vasodila-
tors (endothelium and nonendothelium dependent) was 
not tested in this study. Both desensitization and aug-
mentation appear to be valid options.
 Pertinently, the dilatation induced by albumin did not 
quite reach a steady state during our observation time of 
20 min, likely due to a positive feedback mechanism: 
shear stress leads to NO-mediated vasodilatation, where-
upon the coronary flow increases; consequently, the shear 
stress increases again somewhat. In this context, atten-
tion must be drawn to the fact that both, the mode of per-
fusion (constant pressure) and the style of preparation 
(incompetent mitral valve precluding the performance of 
any pressure-volume work), were chosen to augment such 
feedback possibilities. Accordingly, during constant flow 
perfusion supplementing perfusate with albumin elicits 
only a small, self-limiting drop in steady-state coronary 
perfusion pressure, i.e., due to negative feedback only a 
limited vasodilatory response is to be observed  [8] .
 The isolated perfused heart as prepared here (Langen-
dorff mode) per definition does not perform any pressure-
volume work. Nevertheless, coronary flow is under a cer-
tain degree of metabolic control. Changes in coronary 
flow, of course, change oxygen delivery to the heart prep-
aration. Thus, albumin-induced dilatation will be coun-
teracted to some extent by an autoregulatory increase in 
vascular tone, while flow reduction due to perfusion with 
a medium of a higher viscosity (KHB + 1/3 volume HES 
450) will elicit some reactive metabolic dilatation. How-
ever, from previous work it is known that delivery of oxy-
gen via perfusates without hemoglobin does not limit ox-
ygen consumption. In fact, there is considerable ‘luxury’ 
perfusion  [33, 35] . The effects of altered supply on coro-
nary reaction are, therefore, very much attenuated and 
have not been considered further in the present study. 
Since the PO 2  of all perfusates was identical (approxi-
mately 400 mm Hg), metabolic regulation should not have 
elicited flows different from those observed with KHB + 
vehicle (control groups receiving 0.9% saline).
 The reason why albumin causes an effect far larger 
than that observed during infusion of artificial colloids 
could relate to a specific interaction of the natural colloid 
with the glycocalyx. By virtue of its amphiphilic nature, 
i.e., the presence of both negatively and positively charged 
groups in the molecule, albumin forms a complete ESL 
 [2, 4, 8, 15] . In contrast, the glycocalyx represents an ex-
clusion zone for large neutral and anionic molecules like 
dextrans  6 70 kDa  [36, 37] and it may be expected that 
other large molecules carrying an exclusively negative 
charge, such as HES, also do not interact well with an in-
tact EG. Accordingly, an albumin-containing perfusate 
should ‘hook’ into this structure, transmitting shear 
stress to the vessel wall, while artificial colloids like HES, 
figuratively speaking, brush only against the top of the 
glycocalyx molecules  [38] . Such a difference is reflected 
by the similarity in intravascular distribution spaces of 
HES and red blood cells in vivo, as opposed to those trac-
ers binding to albumin  [39, 40] . This interpretation is also 
in line with our previous work concerning the barrier 
function of the EG  [4, 8, 17] , which is also overpropor-
tionally enhanced by albumin versus HES  [8] . Owing to 
the different quality of the ESL, it is understandable why 
there was only an insignificant mean increase in coro-
nary flow in the HES groups in comparison to perfusion 
with colloid-free buffer, and why no simple relationship 
existed to dynamic viscosity of the various perfusates.
 Notwithstanding, from comparing the coronary flows 
after heparinase pretreatment and during NO- L -Ag ap-
plication, it can be derived that colloids are able to medi-
ate some shear stress to the vessel wall, even after most of 
the negative charges have been stripped from the EG with 
heparinase. The difference was significant in the experi-
ments with KHB augmented with HES 450. As demon-
strated previously, heparinase is an enzyme specific for 
heparan sulfates and, therefore, has the ability to alter 
thickness  [1, 3, 4] and barrier function  [4, 17, 34, 41] of 
the glycocalyx. However, as revealed by electron micros-
copy at a high magnification in this work, small regions 
of glycocalyx remain also after heparinase pretreatment, 
likely representing a scaffold of syndecans and glypicans 
minus side chains. Obviously, HES molecules with the 
high molecular weight of 450 kDa are big enough to in-
teract mechanically with a rudimentary glycocalyx, caus-
ing some increase in coronary flow sensitive to inhibition 
of the NO synthase.
 Surprisingly, in the presence of NO- L -Ag, the flow 
with perfusate containing HES 450 did not differ from 
that of control hearts perfused with NO- L -Ag (see  fig. 3 ; 
 table 1 ), despite the different perfusate viscosity. Since 
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NO- L -Ag is expected to inhibit both, stimulated and bas-
al NO production, some residual dilatory mechanism 
must still be active for HES 450 in the absence of NO gen-
eration. The same conclusion as for HES 450 may be 
drawn in the case of albumin. Here too, NO- L -Ag did not 
fully inhibit the rise in coronary flow induced by albumin 
versus control. These phenomena could relate to induc-
tion of endothelium-derived hyperpolarizing factor or 
prostacyclin by shear stress.
 Numerous studies have examined shear stress-medi-
ated actions on cultured endothelial cells, but only few 
even considered the relationship between the EG and 
shear stress-induced effects. For example, Florian et al. 
 [19]  stated, due to qualitative staining of heparan sulfate 
via a fluorescent antibody  in a bovine aortic endothelial 
cell monolayer, that they were dealing with an EG in their 
model. Ueda et al. [39] delivered electron-microscopic 
pictures of the EG in a comparable model after staining 
with ruthenium red. The resulting absolute thickness is 
not quantified, but according to the presented scale in 
their figures, we would estimate it to be less than 50 nm. 
In contrast, by stabilizing the EG with La 3+  during fixa-
tion we measured a thickness of at least 300 nm for the 
healthy, colloid-free glycocalyx, as also reported previous-
ly  [4, 8, 14, 16] . On the basis of our electron-microscopic 
images, the EG of cultured HUVEC should, at best, be 
comparable to that established after heparinase pretreat-
ment of coronary vascular endothelial cells in situ. Con-
sequently, measuring release of NO induced by shear 
stress with cultured cells can, in no way, reflect normal 
behavior of an intact EG. Release of NO due to shear stress 
in this setting could represent an interaction of the per-
fusate with the rudimentary glycocalyx, or it could result 
from direct deformation of the endothelial cell membrane 
by the flowing buffer. In any case, the cultured monolay-
er seems an extremely poor model of the conditions in 
vivo, at least concerning the physiological impact of the 
EG in its capacity to form a competent ESL.
 The discrepancy between cultured endothelial cells 
and the situation in vivo becomes even greater when con-
sidering a shortcoming of our perfusion model, namely 
the absence of plasma constituents possibly augmenting 
formation of the ESL by albumin. Numerous studies have 
suggested that albumin alone is not as effective in reduc-
ing vascular permeability as plasma and serum  [42] . The 
same may hold true with respect to the magnitude of 
shear stress-mediated coronary dilatation.
 In conclusion, the present work highlights the value of 
the physiological plasma component albumin for devel-
oping an ESL and thereby eliciting strong shear stress de-
pendency of vascular dilatation. This interaction should 
help to maintain basal nutritive blood flow, possibly by 
strengthening natural vasomotion and reducing the like-
lihood of capillaries having low or no perfusion. The re-
sults thus suggest a need for reconsidering the widespread 
clinical use of nonphysiological substances as substitutes 
of plasma colloids. At least in critically ill patients, infu-
sion of albumin would seem the better therapeutic 
choice.
 Acknowledgments 
 The authors are very grateful to Ms. S. Herzmann for expert 
technical assistance.
 Studies were supported, in part, by the GEMI Fund, Harvard 
Medical International, USA, and the Karolinska Institute, Stock-
holm, Sweden, as well as by departmental research funding pro-
vided by the Government of Bavaria (Bavarian State Ministry of 
Science, Research, and the Arts, Munich).
 
 References 
 1 Desjardins C, Duling BR: Heparinase treat-
ment suggests a role for the endothelial cell 
glycocalyx in regulation of capillary hema-
tocrit. Am J Physiol 1990;  258:H647–H654. 
 2 Pries AR, Secomb TW: Microvascular blood 
viscosity in vivo and the endothelial surface 
layer. Am J Physiol Heart Circ Physiol 2005; 
 289:H2657–H2664. 
 3 Pries AR, Secomb TW, Jacobs H, Sperandio 
M, Osterloh K, Gaehtgens P: Microvascular 
blood flow resistance: role of endothelial 
surface layer. Am J Physiol 1997;  273:H2272–
H2279. 
 4 Rehm M, Zahler S, Lotsch M, Welsch U, 
Conzen P, Jacob M, Becker BF: Endothelial 
glycocalyx as an additional barrier deter-
mining extravasation of 6% hydroxyethyl 
starch or 5% albumin solutions in the coro-
nary vascular bed. Anesthesiology 2004;  100: 
 1211–1223. 
 5 Vink H, Duling BR: Identification of distinct 
luminal domains for macromolecules, eryth-
rocytes, and leucocytes within mammalian 
capillaries. Circ Res 1996;  79:  581–589. 
 6 Pries AR, Secomb TW, Gaehtgens P: The en-
dothelial surface layer. Pflügers Arch 2000; 
 440:  653–666. 
 7 Constantinescu AA, Vink H, Spaan JA: En-
dothelial cell glycocalyx modulates immobi-
lization of leukocytes at the endothelial sur-
face. Arterioscler Thromb Vasc Biol 2003;  23: 
 1541–1547. 
 8 Jacob M, Bruegger D, Conzen P, Rehm M, 
Becker BF: Contrasting effects of colloid and 
crystalloid resuscitation fluids on cardiac 
vascular permeability. Anesthesiology 2006; 
 104:  1223–1231. 
 9 van den Berg BM, Vink H, Spaan JA: The en-
dothelial glycocalyx protects against myo-
cardial edema. Circ Res 2003;  92:  592–594. 
 Glycocalyx-Mediated Coronary 
Dilatation 
J Vasc Res 2007;44:435–443 443
 10 Risau W: Differentiation of endothelium. 
FASEB J 1995;  9:  926–933. 
 11 Siegel G, Malmsten M: The role of the endo-
thelium in inflammation and tumor metas-
tasis. Int J Microcirc Clin Exp 1997;  17:  257–
272. 
 12 Vink H, Constantinescu AA, Spaan JA: Oxi-
dized lipoproteins degrade the endothelial 
surface layer: implications for platelet-endo-
thelial cell adhesion. Circulation 2000;  101: 
 1500–1502. 
 13 Platts SH, Linden J, Duling BR: Rapid modi-
fication of the glycocalyx caused by isch-
emia-reperfusion is inhibited by adenosine 
A2A receptor activation. Am J Physiol Heart 
Circ Physiol 2003;  284:H2360–H2367. 
 14 Gouverneur M, van den Berg B, Nieuwdorp 
M, Stroes E, Vink H: Vasculoprotective 
properties of the endothelial glycocalyx: ef-
fects of f luid shear stress. J Intern Med 2006; 
 259:  393–400. 
 15 Adamson RH, Lenz JF, Zhang X, Adamson 
GN, Weinbaum S, Curry FE: Oncotic pres-
sures opposing filtration across non-fenes-
trated rat microvessels. J Physiol 2004;  557: 
 889–907. 
 16 Bruegger D, Jacob M, Rehm M, Loetsch M, 
Welsch U, Conzen P, Becker BF: Atrial natri-
uretic peptide induces shedding of the endo-
thelial glycocalyx in the coronary vascular 
bed of guinea pig hearts. Am J Physiol Heart 
Circ Physiol 2005;  289:H1993–H1999. 
 17 Jacob M, Bruegger D, Rehm M, Stoeckelhu-
ber M, Welsch U, Conzen P, Becker BF: The 
endothelial glycocalyx affords compatibility 
of Starling’s principle and high cardiac inter-
stitial albumin levels. Cardiovasc Res 2006; 
 73:  575–586. 
 18 Chang YS, Yaccino JA, Lakshminarayanan 
S, Frangos JA, Tarbell JM: Shear-induced in-
crease in hydraulic conductivity in endothe-
lial cells is mediated by a nitric oxide-depen-
dent mechanism. Arterioscler Thromb Vasc 
Biol 2000;  20:  35–42. 
 19 Florian JA, Kosky JR, Ainslie K, Pang Z, Dull 
RO, Tarbell JM: Heparan sulfate proteogly-
can is a mechanosensor on endothelial cells. 
Circ Res 2003;  93:e136–e142. 
 20 Gonzalez-Castillo C, Rubio R, Zenteno-Sav-
in T: Coronary flow-induced inotropism is 
modulated by binding of dextrans to the en-
dothelial luminal surface. Am J Physiol 
Heart Circ Physiol 2003;  284:H1348–H1357. 
 21 Kuchan MJ, Frangos JA: Role of calcium and 
calmodulin in flow-induced nitric oxide 
production in endothelial cells. Am J Physiol 
1994;  266:C628–C636. 
 22 Mochizuki S, Vink H, Hiramatsu O, Kajita T, 
Shigeto F, Spaan JA, Kajiya F: Role of hyal-
uronic acid glycosaminoglycans in shear-in-
duced endothelium-derived nitric oxide re-
lease. Am J Physiol Heart Circ Physiol 2003; 
 285:H722–H726. 
 23 Rubanyi GM, Romero JC, Vanhoutte PM: 
Flow-induced release of endothelium-de-
rived relaxing factor. Am J Physiol 1986;  250:
H1145–H1149. 
 24 Kohler R, Heyken WT, Heinau P, Schubert R, 
Si H, Kacik M, Busch C, Grgic I, Maier T, 
Hoyer J: Evidence for a functional role of en-
dothelial transient receptor potential V4 in 
shear stress-induced vasodilatation. Arte-
rioscler Thromb Vasc Biol 2006;  26:  1495–
1502. 
 25 Heindl B, Zahler S, Welsch U, Becker BF: 
Disparate effects of adhesion and degranula-
tion of platelets on myocardial and coronary 
function in postischaemic hearts. Cardio-
vasc Res 1998;  38:  383–394. 
 26 Vogel J, Sperandio M, Pries AR, Linderkamp 
O, Gaehtgens P, Kuschinsky W: Influence of 
the endothelial glycocalyx on cerebral blood 
flow in mice. J Cereb Blood Flow Metab 
2000;  20:  1571–1578. 
 27 Ihrcke NS, Wrenshall LE, Lindman BJ, Platt 
JL: Role of heparan sulfate in immune sys-
tem-blood vessel interactions. Immunol To-
day 1993;  14:  500–505. 
 28 Turnbull J, Powell A, Guimond S: Heparan 
sulfate: decoding a dynamic multifunctional 
cell regulator. Trends Cell Biol 2001;  11:  75–
82. 
 29 Asundi VK, Carey DJ: Self-association of N-
syndecan (syndecan-3) core protein is medi-
ated by a novel structural motif in the trans-
membrane domain and ectodomain flanking 
region. J Biol Chem 1995;  270:  26404–26410. 
 30 Bernfield M, Kokenyesi R, Kato M, Hinkes 
MT, Spring J, Gallo RL, Lose EJ: Biology of 
the syndecans: a family of transmembrane 
heparan sulfate proteoglycans. Annu Rev 
Cell Biol 1992;  8:  365–393. 
 31 Pohl U, Herlan K, Huang A, Bassenge E: 
EDRF-mediated shear-induced dilation op-
poses myogenic vasconstriction in small 
rabbit arteries. Am J Physiol 1991;  261:
H2016–H2023. 
 32 Tarbell JM, Pahakis MY: Mechanotransduc-
tion and the glycocalyx. J Intern Med 2007; 
 259:  339–350. 
 33 Bunger R, Haddy FJ, Querengasser A, Ger-
lach E: An isolated guinea pig heart prepara-
tion with in vivo like features. Pflügers Arch 
1975;  353:  317–326. 
 34 Leipert B, Becker BF, Gerlach E: Different 
endothelial mechanisms involved in coro-
nary response to known vasodilators. Am J 
Physiol Heart Circ Physiol 1992;  262:H1676–
H1683. 
 35 Buenger R, Haddy FJ, Gerlach E: Coronary 
response to dilating substances and compet-
ing inhibition by theophylline in the isolated 
perfused guinea pig heart. Pflügers Arch 
1975;  358:  213–224. 
 36 Jacob M, Conzen P, Finsterer U, Krafft A, 
Becker BF, Rehm M: Technical and physio-
logical background of plasma volume mea-
surement with indocyanine green: a clarifi-
cation of misunderstandings. J Appl Physiol 
2007;  102:  1235–1242. DOI: 10.1152/jappl-
physiol.00740.2006. 
 37 Tschaikowsky K, Meisner M, Durst R, 
Rugheimer E: Blood volume determination 
using hydroxyethyl starch: a rapid and sim-
ple intravenous injection method. Crit Care 
Med 1997;  25:  599–606. 
 38 Mulivor AW, Lipowsky HH: Role of glycoca-
lyx in leukocyte-endothelial cell adhesion. 
Am J Physiol Heart Circ Physiol 2002;  283:
H1282–H1291. 
 39 Ueda A, Shimomura M, Ikeda M, Yamagu-
chi R, Tanishita K: Effect of glycocalyx on 
shear-dependent albumin uptake in endo-
thelial cells. Am J Physiol Heart Circ Physiol 
2004;  287:H2287–H2294. 
 40 Vink H, Duling BR: Capillary endothelial 
surface layer selectively reduces plasma sol-
ute distribution volume. Am J Physiol Heart 
Circ Physiol 2000;  278:H285–H289. 
 41 van Haaren P, VanBavel E, Vink H, Spaan JA: 
Localization of the permeability barrier to 
solutes in isolated arteries by confocal mi-
croscopy. Am J Physiol Heart Circ Physiol 
2003;  285:H2848–H2856. 
 42 Huxley VH, Curry FE, Powers MR, Thipak-
orn B: Differential action of plasma and al-
bumin on transcapillary exchange of anion-
ic solute. Am J Physiol 1993;  264:H1428–
H1437. 
 
